Charging Robotics (CHEV) 10-Q 16 Aug 23 2023 Q2 Quarterly report Financial data

Document And Entity Information

Document And Entity Information - shares	6 Months Ended
	Jun. 30, 2023	Aug. 16, 2023
Document Information Line Items
Entity Registrant Name	FUEL DOCTOR HOLDINGS, INC.
Document Type	10-Q
Current Fiscal Year End Date	--12-31
Entity Common Stock, Shares Outstanding		1,372,656,029
Amendment Flag	false
Entity Central Index Key	0001459188
Entity Current Reporting Status	Yes
Entity Filer Category	Non-accelerated Filer
Document Period End Date	Jun. 30, 2023
Document Fiscal Year Focus	2023
Document Fiscal Period Focus	Q2
Entity Small Business	true
Entity Emerging Growth Company	false
Entity Shell Company	false
Document Quarterly Report	true
Document Transition Report	false
Entity File Number	000-56253
Entity Incorporation, State or Country Code	DE
Entity Tax Identification Number	26-2274999
Entity Address, Address Line One	20 Raul Wallenberg Street
Entity Address, City or Town	Tel Aviv
Entity Address, Country	IL
City Area Code	(647)
Local Phone Number	558-5564
Entity Interactive Data Current	Yes
Entity Address, Postal Zip Code	00000

Condensed Consolidated Balance

Condensed Consolidated Balance Sheets - USD ($) $ in Thousands	Jun. 30, 2023	Dec. 31, 2022
Current assets:
Cash	$ 254	$ 27
Other accounts receivable	47	71
Total current assets	301	98
Non current assets:
Investment in an affiliate (Note 4c)	133	152
Intangible asset (Note 5)	85	74
Loan to an affiliate (Note 4b)	61	60
Total non current assets	279	286
TOTAL ASSETS	580	384
Current liabilities:
Accounts payable	50	108
Related parties (Note 6)	66	595
Other current liabilities	22
Total current liabilities	138	703
Deferred revenues	49	49
Total liabilities	187	752
Stockholders’ equity (Note 7)
Preferred shares, par value $0.0001, 10,000,000 shares authorized, 0 shares issued and outstanding at June 30, 2023 and December 31, 2022
Common stock, par value $0.0001, 2,990,000,000 shares authorized, 1,372,656,029 shares issued and outstanding at June 30, 2023 and 2,990,000,000 shares authorized, 27,273 shares issued and outstanding at December 31, 2022	137
Additional paid-in capital	1,681	741
Foreign currency transaction reserve	(19)	(12)
Reserve from share-based compensation transactions	98	91
Accumulated deficit	(1,504)	(1,188)
Total stockholders’ equity (deficit)	393	(368)
TOTAL LIABILITIES AND STOCKHOLDERS’ EQUITY	$ 580	$ 384

Condensed Consolidated Balanc_2

Condensed Consolidated Balance Sheets (Parentheticals) - $ / shares	Jun. 30, 2023	Dec. 31, 2022
Statement of Financial Position [Abstract]
Preferred shares, par value (in Dollars per share)	$ 0.0001	$ 0.0001
Preferred shares, shares authorized	10,000,000	10,000,000
Preferred shares, shares issued	0	0
Preferred shares, outstanding	0	0
Common stock, par value (in Dollars per share)	$ 0.0001	$ 0.0001
Common stock, shares authorized	2,990,000,000	2,990,000,000
Common stock, shares issued	1,372,656,029	27,273
Common stock, shares outstanding	1,372,656,029	27,273

Condensed Consolidated Statemen

Condensed Consolidated Statements of Operations (Unaudited) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2023	Jun. 30, 2022	Jun. 30, 2023	Jun. 30, 2022
Income Statement [Abstract]
Research and development costs	$ 37	$ 151	$ 149	$ 364
General and administrative costs	144	32	156	92
Operating loss	(181)	(183)	(305)	(456)
Financial expenses
Net loss	(181)	(183)	(305)	(456)
Share in losses of affiliate	(10)	(5)	(11)	(9)
Net loss for the period	(191)	(188)	(316)	(465)
Other comprehensive loss	(7)	(19)	(7)	(24)
Net loss and comprehensive loss for the period	$ (198)	$ (207)	$ (323)	$ (489)
Basic and diluted loss per common share (in Dollars per share)	$ 0	$ (7.59)	$ 0	$ (17.93)
Weighted average common shares outstanding (in Shares)	1,220,569,717	27,273	613,670,159	27,273

Condensed Consolidated Statem_2

Condensed Consolidated Statements of Operations (Unaudited) (Parentheticals) - $ / shares	3 Months Ended		6 Months Ended
	Jun. 30, 2023	Jun. 30, 2022	Jun. 30, 2023	Jun. 30, 2022
Income Statement [Abstract]
Diluted loss per common share	$ 0	$ (7.59)	$ 0	$ (17.93)

Condensed Consolidated Statem_3

Condensed Consolidated Statements of Stockholders’ Equity (Deficit) (Unaudited) - USD ($) $ in Thousands	Ordinary shares	Additional Paid in capital	Stock-based compensation	Accumulated other comprehensive loss	Accumulated Deficit	Total
Balance at Dec. 31, 2021		$ 741	$ 76	$ 11	$ (378)	$ 450
Balance (in Shares) at Dec. 31, 2021	27,273
Share based payment reserve			7			7
Net comprehensive loss for the period				(24)	(465)	(489)
Balance at Jun. 30, 2022		741	83	(13)		(843)
Balance (in Shares) at Jun. 30, 2022	27,273
Balance at Dec. 31, 2022		741	91	(12)	(1,188)	(368)
Balance (in Shares) at Dec. 31, 2022	27,273
Exercise of options		91	7			98
Exercise of options (in Shares)	4,091
Issuance of shares in respect of converted loan		509				509
Issuance of shares in respect of converted loan (in Shares)	7,636
Effect of reverse merger	$ 124	(148)				(24)
Effect of reverse merger (in Shares)	1,236,117,029
Issuance of shares in respect of private placement	$ 13	488				501
Issuance of shares in respect of private placement (in Shares)	136,500,000
Net comprehensive loss for the period				(7)	(316)	(323)
Balance at Jun. 30, 2023	$ 137	$ 1,681	$ 98	$ (19)	$ (1,504)	$ 393
Balance (in Shares) at Jun. 30, 2023	1,372,656,029

Condensed Consolidated Statem_4

Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($) $ in Thousands	6 Months Ended
	Jun. 30, 2023	Jun. 30, 2022
CASH FLOWS FROM OPERATING ACTIVITIES:
Net loss	$ (316)	$ (465)
Adjustments to reconcile net loss to net cash (used) in operating activities:
Share-based payment expenses	7	7
Share in losses of affiliate	11	8
Interest income	(1)
Changes in operating assets and liabilities:
Decrease (increase) in other accounts receivable	24	(6)
Increase (decrease) in related parties	(20)	138
Increase (decrease) in accounts payable	(58)	62
Increase in other accounts payable and accrued expenses	11	130
Net cash provided by operating activities	(342)	(126)
CASH FLOWS (USED IN) INVESTING ACTIVITIES:
Increase in other accounts receivable		(36)
Net cash (used in) investing activities		(36)
CASH FLOWS FROM FINANCING ACTIVITIES:
Proceeds from issuance of shares in respect of a private placement	501
Proceeds from exercise of options	91
Net cash provided by financing activities	592
Net (decrease) increase in cash	250	(162)
Effect of changes in foreign exchange rates	1
Effect of reverse merger	(24)
Cash at beginning of period	27	167
Cash at end of period	254	5
SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION:
Interest
Franchise taxes
SUPPLEMENTAL DISCLOSURE OF NON-CASH ACTIVITIES:
Issuance of shares to in respect of converted loan	509
Investment in intangible asset	$ 11

General

General	6 Months Ended
	Jun. 30, 2023
General [Abstract]
GENERAL	NOTE 1 – GENERAL Fuel Doctor Holdings, Inc. (“Fuel Doctor” or the “Company”) was incorporated in the state of Delaware on March 25, 2008 as Silver Hill Management Services, Inc. On August 24, 2011, the Company changed its name to Fuel Doctor Holdings, Inc. On January 6, 2022, Amitay Weiss, Asaf Itzhaik and Moshe Revach were appointed to fill existing vacancies on the Company’s Board of Directors in accordance with the written consent of majority of directors dated January 6, 2022. None of the newly appointed Directors had a prior relationship with the Company. In addition, on January 6, 2022, Amitay Weiss was appointed as the Chief Executive Officer of the Company and on January 26, 2022, Gadi Levin was appointed Chief Financial Officer of the Company. On March 28, 2023, the Company entered into a Securities Exchange Agreement (the “Acquisition Agreement”) with the stockholders of Charging Robotics Ltd. (“Charging Robotics”). Pursuant to the Acquisition Agreement, at the closing, which occurred on April 7, 2023, the Company acquired 100% of the issued and outstanding stock of Charging Robotics (the “Acquisition”), making Charging Robotics a wholly owned subsidiary of the Company, in exchange for the issuance of a total of 921,750,000 newly issued shares of the Company’s common stock. The transaction between the Company and Charging Robotics was accounted for as a reverse recapitalization. As the shareholders of Charging Robotics received the largest ownership interest in the Company, based upon the 921,750,000 shares issued at the closing, and the 922,500,000 warrants exercisable at par and most significantly, the fact that the Share Exchange Agreement expressly provided that a majority of the Company’s board of directors could be appointed by Charging Robotics, Charging Robotics was determined to be the “accounting acquirer” in the reverse recapitalization. As a result, the historical financial statements of the Company were replaced with the historical financial statements of Charging Robotics. Charging Robotics was formed in February 2021, as an Israeli corporation, to focus on an innovative wireless electric vehicles (EV) charging technology. At the heart of the technology is a wireless power transfer module that uses resonance coils to transfer electricity wirelessly. This module can be used for various products such as robotic and stationary platforms. The robotic platform will be small enough to fit under the vehicle, will automatically position itself for maximum efficiency charging and will return to its docking station at the end of the charging operation. In parallel, we are also in the final stages of developing a Wireless EV Charging System for automatic parking lots based on our wireless electricity transfer module. On April 6, 2023, the Company issued a total of 136,500,000 newly issued shares of the Company’s common stock in respect of a private placement for total proceeds of $500.

Unaudited Interim Condensed Fin

Unaudited Interim Condensed Financial Statements	6 Months Ended
	Jun. 30, 2023
Unaudited Interim Condensed Financial Statements [Abstract]
UNAUDITED INTERIM CONDENSED FINANCIAL STATEMENTS	NOTE 2 – UNAUDITED INTERIM CONDENSED FINANCIAL STATEMENTS The financial statements were prepared in accordance with accounting principles generally accepted in the United States of America (US GAAP). a. Use of estimates: The preparation of financial statements in conformity with US GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the dates of the financial statements, and the reported amounts of expenses during the reporting periods. Actual results could differ from those estimates. As applicable to these financial statements, the most significant estimates and assumptions relate to shares based compensation and Going concern. b. Financial statements in U.S. dollars: The costs of the Company are denominated in United States dollars (“dollars”). Some of the costs in our Israeli associate are incurred in New Israeli Shekels (NIS), however the selling prices will be linked to the Company’s price list which will be determined in dollars, the budget is managed in dollars, financing activities including loans and cash investments, are made in U.S. dollars and the Company’s management believes that the dollar is the primary currency of the economic environment in which the Company and its subsidiary operates. Thus, the dollar is the Company’s and its subsidiary functional and reporting currency. Accordingly, transactions denominated in currencies other than the functional currency are re-measured to the functional currency in accordance with Accounting Standards Codification (“ASC”) No. 830, “Foreign Currency Matters” at the exchange rate at the date of the transaction or the average exchange rate in the relevant reporting period. At the end of each reporting period, financial assets and liabilities are re-measured to the functional currency using exchange rates in effect at the balance sheet date. Non-financial assets and liabilities are re-measured at historical exchange rates. Gains and losses related to re-measurement are recorded as financial income (expense) in the statements of operations as appropriate. The functional currency of the affiliate company is the NIS and therefore foreign exchange differences are charged to the other comprehensive profit and loss. c. Cash and cash equivalents: Cash equivalents are short-term highly liquid investments which include short term bank deposits (up to three months from date of deposit), that are not restricted as to withdrawals or use that are readily convertible to cash with maturities of three months or less as of the date acquired. d. Investment in affiliated companies Affiliated company is company held to the extent of 20% or more (which are not subsidiary), or company less than 20% held, which the Company can exercise significant influence over operating and financial policy of the affiliate. The investment in affiliated company is accounted for by the equity method under ASC Subtopic 323-30, “Investments - Equity Method and Joint Ventures: Partnerships, Joint Ventures , and Limited Liability Entities”. Upon initial recognition, the cost of investment is based on the direct costs of acquiring the investment including amounts incurred on behalf of the investee. Following the acquisition, the Company recognizes its proportionate share of the affiliated company’s net income or loss after the date of investment. When previous losses have reduced the common stock investment account to zero, the Company continues to report its share of equity method losses in its statement of operations to the extent of and as an adjustment to other investments in the investee such as debt securities, long term loans or advances, if any. Such additional equity method losses are applied to the other investments based on the seniority of the other investments (priority in liquidation) and the percentage ownership interest in each type of other investment the Company holds (the ‘relative holdings approach’). e. Impairment of long-lived assets: The Company’s long-lived assets are reviewed for impairment in accordance with ASC No. 360, “Property, Plant and Equipment” whenever events or changes in circumstances indicate that the carrying amount of an asset (or asset group) may not be recoverable. Recoverability of assets (or asset group) to be held and used is measured by a comparison of the carrying amount of an asset to the future undiscounted cash flows expected to be generated by the assets. If such assets are considered to be impaired, the impairment to be recognized is measured by the amount by which the carrying amount of the assets exceeds the fair value of the assets. During the year ended December 31, 2022, no impairment losses have been recorded. f. Concentration of credit risks: Financial instruments that potentially subject the Company to credit risk consist of cash and cash equivalents and restricted bank deposit. Cash and cash equivalents and restricted bank deposit are invested in major banks in Israel and the United States. Such funds in the Israel may be in excess of insured limits and are not insured in other jurisdictions. Management believes that the financial institutions that hold the Company and its subsidiary’ cash and cash equivalents have high credit ratings. The Company, have no off-balance-sheet concentration of credit risk such as foreign exchange contracts, option contracts or other foreign hedging arrangements. g. Research and development expenses: Research and development costs are charged to the statement of operations as incurred. h. Fair value of financial instruments: ASC Topic 820, “Fair Value Measurements and Disclosures” (“ASC 820”), defines fair value as the price that would be received to sell an asset or paid to transfer a liability (i.e., the “exit price”) in an orderly transaction between market participants at the measurement date. In determining fair value, the Company uses various valuation approaches. ASC 820 establishes a hierarchy for inputs used in measuring fair value that maximizes the use of observable inputs and minimizes the use of unobservable inputs by requiring that the most observable inputs be used when available. Observable inputs are inputs that market participants would use in pricing the asset or liability developed based on market data obtained from sources independent of the Company. Unobservable inputs are inputs that reflect the Company’s assumptions about the assumptions market participants would use in pricing the asset or liability developed based on the best information available in the circumstances. The hierarchy is broken down into three levels based on the inputs as follows: Level 1 — Valuations based on quoted prices in active markets for identical assets that the Company has the ability to access. Level 2 — Valuations based on one or more quoted prices in markets that are not active or for which all significant inputs are observable, either directly or indirectly. Level 3 — Valuations based on inputs that are unobservable and significant to the overall fair value measurement. The fair value hierarchy also requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. The carrying amounts of cash and cash equivalents, other current assets, accounts payables and current liabilities approximate their fair value due to the short-term maturity of such instruments. i. Income Tax: The Company account for income taxes in accordance with ASC 740, “Income Taxes” which prescribes the use of the liability method whereby deferred tax assets and liability account balances are determined based on differences between financial reporting and tax bases of assets and liabilities and are measured using the enacted tax rates and laws that will be in effect when the differences are expected to reverse. The Company provides a valuation allowance, if necessary, to reduce deferred tax assets to their estimated realizable value if it not is more likely than not that a portion or all of the deferred tax assets will be realized. Based on ASC 740, a two-step approach is used to recognize and measure uncertain tax positions. The first step is to evaluate the tax position taken or expected to be taken in a tax return by determining if the weight of available evidence indicates that it is more likely than not that, on an evaluation of the technical merits, the tax position will be sustained on audit, including resolution of any related appeals or litigation processes. The second step is to measure the tax benefit as the largest amount that is more than 50% likely to be realized upon ultimate settlement. As of December 31, 2022, no liability for unrecognized tax positions has been recorded. Accordingly, no interest or penalties related to uncertain tax positions are recorded, either. It is the Company’s policy that any interest or penalties associated with unrecognized tax positions would be reflected in income tax expense. j. Contingencies: The Company records accruals for loss contingencies arising from claims, litigation and other sources when it is probable that a liability has been incurred and the amount can be reasonably estimated. These accruals are adjusted periodically as assessments change or additional information becomes available. Legal costs incurred in connection with loss contingencies are expensed as incurred. k. Stock-based payments: The Company measures and recognizes the compensation expense for all equity-based payments to employees based on their estimated fair values in accordance with ASC 718, “Compensation-Stock Compensation”. Share-based payments including grants of stock options are recognized in the statement of comprehensive loss as an operating expense based on the fair value of the award at the date of grant. The fair value of stock options granted is estimated using the Black-Scholes option-pricing model. The Company has expensed compensation costs, net of estimated forfeitures, applying the accelerated vesting method, over the requisite service period or over the implicit service period when a performance condition affects the vesting, and it is considered probable that the performance condition will be achieved. Share-based payments awarded to consultants (non-employees) are accounted for in accordance with ASC Topic 505-50, “Equity-Based Payments to Non-Employees”. For year ended December 31, 2022, the Company recorded $15, in share-based compensation (see note 5(b)). Basis of Presentation and Principles of Consolidation: The accompanying unaudited condensed consolidated financial statements include the accounts of the Company and its wholly-owned subsidiary and were prepared in accordance with Generally Accepted Accounting Principles in the United States of America (“GAAP”) All intercompany accounts and transactions have been eliminated in consolidation. Unaudited Interim Financial Information The Company’s unaudited condensed consolidated financial statements have been prepared in accordance with GAAP and pursuant to the rules and regulations of the Securities and Exchange Commission (the “SEC”). Certain information and footnote disclosures normally included in financial statements prepared in accordance with GAAP have been condensed or omitted from this report, as is permitted by such rules and regulations. In the opinion of management, the accompanying unaudited condensed consolidated financial statements include all adjustments, consisting of a normal recurring nature, which are necessary for a fair presentation of the financial position, operating results and cash flows for the periods presented. The unaudited condensed consolidated financial statements have been prepared on the same basis as the audited consolidated financial statements. In the opinion of the Company’s management, the accompanying unaudited condensed financial statements contain all adjustments that are necessary to present fairly the Company’s financial position and results of operations for the interim periods presented. The results for the six months ended June 30, 2023, are not necessarily indicative of the results for the year ending December 31, 2023, or for any future period. Accordingly, these condensed consolidated financial statements should be read in conjunction with the audited financial statements as of and for the year ended December 31, 2022, and the notes thereto included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2022 filed with the SEC on February 21, 2023 (the “2022 Annual Report”). As of June 30, 2023, there have been no material changes in the Company’s significant accounting policies from those that were disclosed in the 2022 Annual Report.

Going Concern

Going Concern	6 Months Ended
	Jun. 30, 2023
Going Concern [Abstract]
GOING CONCERN	NOTE 3 – GOING CONCERN The condensed consolidated financial statements have been prepared on a going concern basis which assumes the Company will be able to realize its assets and discharge its liabilities in the normal course of business for the foreseeable future. The Company has incurred a loss since Inception resulting in an accumulated deficit of $1,188 as of December 31, 2022 and $1,504 as of June 30, 2023 and further losses are anticipated in the development of its business. Management expects the Company to continue to generate substantial operating losses and to continue to fund its operations primarily through utilization of its current financial resources and through additional raises of capital. Such conditions raise substantial doubts about the Company’s ability to continue as a going concern. Management’s plan includes raising funds from outside potential investors. However, there is no assurance such funding will be available to the Company or that it will be obtained on terms favorable to the Company or will provide the Company with sufficient funds to meet its objectives. These consolidated financial statements do not include any adjustments relating to the recoverability and classification of assets, carrying amounts or the amount and classification of liabilities that may be required should the Company be unable to continue as a going concern.

Investment in Affiliated Compan

Investment in Affiliated Company	6 Months Ended
	Jun. 30, 2023
Investment in Affiliated Company [Abstract]
INVESTMENT IN AFFILIATED COMPANY	NOTE 4 – INVESTMENT IN AFFILIATED COMPANY a. On April 24, 2021 (“Closing Date”), Charging Robotics invested $250 and purchased 19.99% of the share capital of Revoltz Ltd (“Revoltz”), an Israeli private company focusing on research, development and production of micro-mobility vehicles for the urban environment for the business and the private markets. b. On July 28, 2022, the Charging Robotics entered into a convertible loan agreement with Revoltz pursuant to which Charging Robotics was required to invest an amount of $60 in Revoltz (the “Loan Principal Amount”). In addition, the Charging Robotics provided to Revoltz further lending of up to $340 (the “Additional Amount”, and together with the Loan Principal, the “Total Loan Amount”). The Total Loan Amount shall carry interest at the minimum rate prescribed by Israeli law. The Total Loan Amount shall be converted into shares of Revoltz, upon the occurrence of any of the following events (each a “Trigger Event”): i) The consummation of funding by Revoltz of an aggregate amount of $1,000 at a pre-money Revoltz valuation of at least $7,000 (in the form of SAFE, equity or otherwise); ii) Revoltz has generated an aggregate of $1,000 or more in revenue. In the event that a Trigger Event shall not have occurred on or prior to the 24-month anniversary of the date on which the Loan Principal Amount is actually extended to Revoltz, the Loan shall be due and repayable by Revoltz to the Company. On June 30, 2023, the balance of the Loan Principal Amount granted was $61. c. The following table summarizes the equity method accounting for the investment in affiliated company: Balance January 1, 2022 217 Share in losses of affiliated company (42 ) Foreign currency translation (23 ) Balance December 31, 2022 152 Share in losses of affiliated company (11 ) Foreign currency translation (8 ) Balance June 30, 2023 133

Intangible Asset

Intangible Asset	6 Months Ended
	Jun. 30, 2023
Intangible Asset [Abstract]
INTANGIBLE ASSET	NOTE 5 – INTANGIBLE ASSET The Company considers all intangibles to be definite-lived assets with lives of 20 years. The Company will start amortization at the end of the product development. Intangibles consisted of the following on June 30, 2023 and December 31, 2022: Balance, January 1, 2022 $ 74 Additions - Balance, December 31, 2022 $ 74 Additions 11 Balance, June 30, 2023 $ 85

Related Parties

Related Parties	6 Months Ended
	Jun. 30, 2023
Related Parties [Abstract]
RELATED PARTIES	NOTE 6 – RELATED PARTIES a. In support of the Company’s efforts and cash requirements, the Company may rely on advances from related parties until such a time that the Company can support its operations or attains adequate financing through sales of stock or traditional debt financing. There is no formal written commitment for continued support by related parties. (i) The compensation to key management personnel for employment services they provide to the Company is as follows: Three Months Ended Six Months Ended 2023 2022 2023 2022 Consulting Fees – CEO $ 21 $ 21 $ 42 $ 42 Consulting Fees - CFO $ 11 $ 2 $ 20 $ 6 No director fees were paid during the six months ended June 30, 2023 and 2022. (ii) Balances owed to related parties June 30, December 31, 2023 2022 Consulting Fees - CEO $ 14 $ 28 Consulting Fees - CFO 4 17 Medigus 48 550 $ 66 $ 595 b. The Company currently operates out of an office of a related party free of rent. c. As of January 1, 2023, Charging Robotics owed a related party $550 (“Medigus Loan”). The Medigus Loan bears interest in accordance with section 3(i) of the Israeli tax code (2.42% annually during 2022) and no fixed date for repayment has been determined. On January 1, 2023, Charging Robotics and Medigus signed an agreement to amend the terms of the Medigus Loan (“Medigus Loan Agreement”). Pursuant to the Medigus Loan Agreement, the interest rate remains unchanged, and the capital and interest will be repaid in cash or shares, or a combination thereof by the earlier of (i) the completion of the Medigus Transaction or (ii) June 30, 2023. On April 4, 2023, the Medigus Loan balance owing was $553. $509 of the Medigus Loan was converted into 28 shares of Charging Robotics and the balance will be repaid in cash. d. On October 1, 2021, Charging Robotics signed a consulting agreement with the CEO, pursuant to which Charging Robotics will pay the CEO a monthly fee of NIS 24,700 (approximately $7). Subject to approval of Charging Robotics’ board of directors (“Board”), the CEO shall be entitled to receive stock options in the Company that will entitle him to own 3% of Charging Robotics. The options will have an exercise price equivalent to a Charging Robotics valuation of $10,000. As of the date of this report, the options have not been issued as the Board has not yet approved their issuance. During the six months ended June 30, 2023, the CEO earned $42 (during the six months ended June 30, 2022 - $42).

Common Stock and Preferred Stoc

Common Stock and Preferred Stock	6 Months Ended
	Jun. 30, 2023
Common Stock and Preferred Stock [Abstract]
COMMON STOCK AND PREFERRED STOCK	NOTE 7 – COMMON STOCK AND PREFERRED STOCK a. As of June 30, 2023, and December 31, 2022, the Company’s share capital is composed as follows: June 30, December 31, Authorized Issued and Authorized Issued and Shares of common stock (“Shares”) 2,990,000,000 1,372,656,029 2,990,000,000 27,273 Preferred shares 10,000,000 - 10,000,000 - On March 22, 2022, the Company Amended the Articles of Incorporation and increased the number of authorized shares to 3,000,000,000 with a par value of $0.0001 of which 2,990,000,000 shares shall be common stock with a par value of $0.0001 and 10,000,000 shares shall be preferred stock with a par value of $0.0001. There were no shares of preferred stock outstanding at June 30, 2023, and December 31, 2022. Each Ordinary share is entitled to receive dividend, participate in the distribution of the Company’s net assets upon liquidation and to receive notices of participate and vote (at one vote per share) at the general meetings of the Company on any matter upon which the general meeting is authorized. On April 3, 2023, prior to the Acquisition Agreement (See note 1), Charging Robotics issued 15 shares of Charging Robotics representing 4,091 shares of the Company, in respect of option exercises for total proceeds of $91. On April 3, 2023, prior to the Acquisition Agreement, the Company issued 28 shares of Charging Robotics representing 7,636 shares of the Company, in respect of a converted loan from a related party (See Also note 6c). On March 28, 2023, Medigus, Charging Robotics and the Company signed a securities exchange agreement pursuant to which the Company is to acquire 100% of the stock of Charging Robotics (the “Acquisition”), making Charging Robotics a wholly owned subsidiary of the Company and shareholders of the Charging Robotics will receive 72.88% of the issued and outstanding share capital of the Company. On April 4, 2023, the Acquisition closed, and the shareholders of Charging Robotics were issued 921,750,000 shares of the Company. On April 6, 2023, the Company sold a total of 136,500,000 newly issued shares of the Company’s common stock to a total of three investors for a total of $501. b. Warrants: Pursuant to the Acquisition (as defined in note 1), the Company issued the previous shareholders of Charging Robotics 922,500,000 warrants exercisable upon the Company achieving each of the three (3) performance milestones (“the Earn Out Milestones”) as follows: (i) Inhouse demonstration for automatic robotic charging of an electric vehicle – until December 31, 2025. (ii) Conditional PO for first system for automatic car parks – until December 31, 2025. (iii) Commercial agreement for pilot with an organization which was approved by the board – until December 31, 2025. All Earn Out Milestones shall immediately accelerate upon the Company uplisting to the Nasdaq stock exchange. c. Share option in the Company As of June 30, 2023 and December 31, 2022 there are no outstanding options in the Company d. Share options in Charging Robotics On February 1, 2022, Charging Robotics issued 4 BGU Options, effective January 1, 2022. The fair value of the BGU Options granted was $30 using the Black-Scholes option pricing model using the following assumptions: January Charging Robotics share price $ 7,410 Charging Robotics Exercise price $ 0 Dividend yield 0 % Risk-free interest rate 0.48 % Expected term (in years) 10 Volatility 75 % For the six months ended June 30, 2023, the Company recorded $7 in share-based compensation expenses in respect of the BGU Options (during the six months ended June 30, 2022 - $7). A summary of stock options activity during the period is as follows: Number Average Options outstanding at December 31, 2021 18 $ 8,333 Granted 4 - Options outstanding at December 31, 2022 22 $ 6,818 Exercised (18 ) 8,333 Options outstanding at June 30, 2023 4 $ - Options exercisable at December 31, 2022 - $ - The following Charging Robotics options are outstanding as of June 30, 2023: Issuance date Options Exercise Options Expiry date January 1, 2022 4 $ - - January 1, 2032 The following Charging Robotics options are outstanding as of December 31, 2022: Issuance date Options Exercise Options Expiry date January 7, 2021 18 $ 8,333 18 January 7, 2026 January 1, 2022 4 $ - - January 1, 2032 22 18

Subsequent Events

Subsequent Events	6 Months Ended
	Jun. 30, 2023
Subsequent Events [Abstract]
SUBSEQUENT EVENTS	NOTE 8 – SUBSEQUENT EVENTS The Company evaluated all other events or transactions that occurred through August 16, 2023. The Company determined that it does not have any other subsequent event requiring recording or disclosure in the financial statements for the six months ended June 30, 2023, other than described below: On July 4, 2023, the Company approved stock option and restricted share unit (“RSU”) plan the “Plan”) for the directors, officers, consultants and employees of the Company and its subsidiary companies. The maximum number of options and RSU’s issuable under the Plan shall be equal to 205,898,404 shares of the outstanding shares of the Company. As of the date of this report, no options or RSU’s were issued.

Accounting Policies, by Policy

Accounting Policies, by Policy (Policies)	6 Months Ended
	Jun. 30, 2023
Accounting Policies [Abstract]
Use of estimates:	a. Use of estimates: The preparation of financial statements in conformity with US GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the dates of the financial statements, and the reported amounts of expenses during the reporting periods. Actual results could differ from those estimates. As applicable to these financial statements, the most significant estimates and assumptions relate to shares based compensation and Going concern.
Financial statements in U.S. dollars:	b. Financial statements in U.S. dollars: The costs of the Company are denominated in United States dollars (“dollars”). Some of the costs in our Israeli associate are incurred in New Israeli Shekels (NIS), however the selling prices will be linked to the Company’s price list which will be determined in dollars, the budget is managed in dollars, financing activities including loans and cash investments, are made in U.S. dollars and the Company’s management believes that the dollar is the primary currency of the economic environment in which the Company and its subsidiary operates. Thus, the dollar is the Company’s and its subsidiary functional and reporting currency. Accordingly, transactions denominated in currencies other than the functional currency are re-measured to the functional currency in accordance with Accounting Standards Codification (“ASC”) No. 830, “Foreign Currency Matters” at the exchange rate at the date of the transaction or the average exchange rate in the relevant reporting period. At the end of each reporting period, financial assets and liabilities are re-measured to the functional currency using exchange rates in effect at the balance sheet date. Non-financial assets and liabilities are re-measured at historical exchange rates. Gains and losses related to re-measurement are recorded as financial income (expense) in the statements of operations as appropriate. The functional currency of the affiliate company is the NIS and therefore foreign exchange differences are charged to the other comprehensive profit and loss.
Cash and cash equivalents:	c. Cash and cash equivalents: Cash equivalents are short-term highly liquid investments which include short term bank deposits (up to three months from date of deposit), that are not restricted as to withdrawals or use that are readily convertible to cash with maturities of three months or less as of the date acquired.
Investment in affiliated companies	d. Investment in affiliated companies Affiliated company is company held to the extent of 20% or more (which are not subsidiary), or company less than 20% held, which the Company can exercise significant influence over operating and financial policy of the affiliate. The investment in affiliated company is accounted for by the equity method under ASC Subtopic 323-30, “Investments - Equity Method and Joint Ventures: Partnerships, Joint Ventures , and Limited Liability Entities”. Upon initial recognition, the cost of investment is based on the direct costs of acquiring the investment including amounts incurred on behalf of the investee. Following the acquisition, the Company recognizes its proportionate share of the affiliated company’s net income or loss after the date of investment. When previous losses have reduced the common stock investment account to zero, the Company continues to report its share of equity method losses in its statement of operations to the extent of and as an adjustment to other investments in the investee such as debt securities, long term loans or advances, if any. Such additional equity method losses are applied to the other investments based on the seniority of the other investments (priority in liquidation) and the percentage ownership interest in each type of other investment the Company holds (the ‘relative holdings approach’).
Impairment of long-lived assets:	e. Impairment of long-lived assets: The Company’s long-lived assets are reviewed for impairment in accordance with ASC No. 360, “Property, Plant and Equipment” whenever events or changes in circumstances indicate that the carrying amount of an asset (or asset group) may not be recoverable. Recoverability of assets (or asset group) to be held and used is measured by a comparison of the carrying amount of an asset to the future undiscounted cash flows expected to be generated by the assets. If such assets are considered to be impaired, the impairment to be recognized is measured by the amount by which the carrying amount of the assets exceeds the fair value of the assets. During the year ended December 31, 2022, no impairment losses have been recorded.
Concentration of credit risks:	f. Concentration of credit risks: Financial instruments that potentially subject the Company to credit risk consist of cash and cash equivalents and restricted bank deposit. Cash and cash equivalents and restricted bank deposit are invested in major banks in Israel and the United States. Such funds in the Israel may be in excess of insured limits and are not insured in other jurisdictions. Management believes that the financial institutions that hold the Company and its subsidiary’ cash and cash equivalents have high credit ratings. The Company, have no off-balance-sheet concentration of credit risk such as foreign exchange contracts, option contracts or other foreign hedging arrangements.
Research and development expenses:	g. Research and development expenses: Research and development costs are charged to the statement of operations as incurred.
Fair value of financial instruments:	h. Fair value of financial instruments: ASC Topic 820, “Fair Value Measurements and Disclosures” (“ASC 820”), defines fair value as the price that would be received to sell an asset or paid to transfer a liability (i.e., the “exit price”) in an orderly transaction between market participants at the measurement date. In determining fair value, the Company uses various valuation approaches. ASC 820 establishes a hierarchy for inputs used in measuring fair value that maximizes the use of observable inputs and minimizes the use of unobservable inputs by requiring that the most observable inputs be used when available. Observable inputs are inputs that market participants would use in pricing the asset or liability developed based on market data obtained from sources independent of the Company. Unobservable inputs are inputs that reflect the Company’s assumptions about the assumptions market participants would use in pricing the asset or liability developed based on the best information available in the circumstances. The hierarchy is broken down into three levels based on the inputs as follows: Level 1 — Valuations based on quoted prices in active markets for identical assets that the Company has the ability to access. Level 2 — Valuations based on one or more quoted prices in markets that are not active or for which all significant inputs are observable, either directly or indirectly. Level 3 — Valuations based on inputs that are unobservable and significant to the overall fair value measurement. The fair value hierarchy also requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. The carrying amounts of cash and cash equivalents, other current assets, accounts payables and current liabilities approximate their fair value due to the short-term maturity of such instruments.
Income Tax:	i. Income Tax: The Company account for income taxes in accordance with ASC 740, “Income Taxes” which prescribes the use of the liability method whereby deferred tax assets and liability account balances are determined based on differences between financial reporting and tax bases of assets and liabilities and are measured using the enacted tax rates and laws that will be in effect when the differences are expected to reverse. The Company provides a valuation allowance, if necessary, to reduce deferred tax assets to their estimated realizable value if it not is more likely than not that a portion or all of the deferred tax assets will be realized. Based on ASC 740, a two-step approach is used to recognize and measure uncertain tax positions. The first step is to evaluate the tax position taken or expected to be taken in a tax return by determining if the weight of available evidence indicates that it is more likely than not that, on an evaluation of the technical merits, the tax position will be sustained on audit, including resolution of any related appeals or litigation processes. The second step is to measure the tax benefit as the largest amount that is more than 50% likely to be realized upon ultimate settlement. As of December 31, 2022, no liability for unrecognized tax positions has been recorded. Accordingly, no interest or penalties related to uncertain tax positions are recorded, either. It is the Company’s policy that any interest or penalties associated with unrecognized tax positions would be reflected in income tax expense.
Contingencies:	j. Contingencies: The Company records accruals for loss contingencies arising from claims, litigation and other sources when it is probable that a liability has been incurred and the amount can be reasonably estimated. These accruals are adjusted periodically as assessments change or additional information becomes available. Legal costs incurred in connection with loss contingencies are expensed as incurred.
Stock-based payments:	k. Stock-based payments: The Company measures and recognizes the compensation expense for all equity-based payments to employees based on their estimated fair values in accordance with ASC 718, “Compensation-Stock Compensation”. Share-based payments including grants of stock options are recognized in the statement of comprehensive loss as an operating expense based on the fair value of the award at the date of grant. The fair value of stock options granted is estimated using the Black-Scholes option-pricing model. The Company has expensed compensation costs, net of estimated forfeitures, applying the accelerated vesting method, over the requisite service period or over the implicit service period when a performance condition affects the vesting, and it is considered probable that the performance condition will be achieved. Share-based payments awarded to consultants (non-employees) are accounted for in accordance with ASC Topic 505-50, “Equity-Based Payments to Non-Employees”. For year ended December 31, 2022, the Company recorded $15, in share-based compensation (see note 5(b)).
Basis of Presentation	Basis of Presentation and Principles of Consolidation: The accompanying unaudited condensed consolidated financial statements include the accounts of the Company and its wholly-owned subsidiary and were prepared in accordance with Generally Accepted Accounting Principles in the United States of America (“GAAP”) All intercompany accounts and transactions have been eliminated in consolidation.
Unaudited Interim Financial Information	Unaudited Interim Financial Information The Company’s unaudited condensed consolidated financial statements have been prepared in accordance with GAAP and pursuant to the rules and regulations of the Securities and Exchange Commission (the “SEC”). Certain information and footnote disclosures normally included in financial statements prepared in accordance with GAAP have been condensed or omitted from this report, as is permitted by such rules and regulations. In the opinion of management, the accompanying unaudited condensed consolidated financial statements include all adjustments, consisting of a normal recurring nature, which are necessary for a fair presentation of the financial position, operating results and cash flows for the periods presented. The unaudited condensed consolidated financial statements have been prepared on the same basis as the audited consolidated financial statements. In the opinion of the Company’s management, the accompanying unaudited condensed financial statements contain all adjustments that are necessary to present fairly the Company’s financial position and results of operations for the interim periods presented. The results for the six months ended June 30, 2023, are not necessarily indicative of the results for the year ending December 31, 2023, or for any future period. Accordingly, these condensed consolidated financial statements should be read in conjunction with the audited financial statements as of and for the year ended December 31, 2022, and the notes thereto included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2022 filed with the SEC on February 21, 2023 (the “2022 Annual Report”). As of June 30, 2023, there have been no material changes in the Company’s significant accounting policies from those that were disclosed in the 2022 Annual Report.

Investment in Affiliated Comp_2

Investment in Affiliated Company (Tables)	6 Months Ended
	Jun. 30, 2023
Investment in Affiliated Company [Abstract]
Schedule of Equity Method Accounting For Investment in Affiliated Company	The following table summarizes the equity method accounting for the investment in affiliated company: Balance January 1, 2022 217 Share in losses of affiliated company (42 ) Foreign currency translation (23 ) Balance December 31, 2022 152 Share in losses of affiliated company (11 ) Foreign currency translation (8 ) Balance June 30, 2023 133

Intangible Asset (Tables)

Intangible Asset (Tables)	6 Months Ended
	Jun. 30, 2023
Intangible Asset [Abstract]
Schedule of All Intangibles to be Definite-Lived Assets	The Company will start amortization at the end of the product development. Intangibles consisted of the following on June 30, 2023 and December 31, 2022: Balance, January 1, 2022 $ 74 Additions - Balance, December 31, 2022 $ 74 Additions 11 Balance, June 30, 2023 $ 85

Related Parties (Tables)

Related Parties (Tables)	6 Months Ended
	Jun. 30, 2023
Related Parties [Abstract]
Schedule of Compensation to Key Management Personnel for Employment Services	The compensation to key management personnel for employment services they provide to the Company is as follows: Three Months Ended Six Months Ended 2023 2022 2023 2022 Consulting Fees – CEO $ 21 $ 21 $ 42 $ 42 Consulting Fees - CFO $ 11 $ 2 $ 20 $ 6 June 30, December 31, 2023 2022 Consulting Fees - CEO $ 14 $ 28 Consulting Fees - CFO 4 17 Medigus 48 550 $ 66 $ 595

Common Stock and Preferred St_2

Common Stock and Preferred Stock (Tables)	6 Months Ended
	Jun. 30, 2023
Common Stock and Preferred Stock [Abstract]
Schedule of Composed Share Capital	As of June 30, 2023, and December 31, 2022, the Company’s share capital is composed as follows: June 30, December 31, Authorized Issued and Authorized Issued and Shares of common stock (“Shares”) 2,990,000,000 1,372,656,029 2,990,000,000 27,273 Preferred shares 10,000,000 - 10,000,000 -
Schedule of Stock Options Granted Using Black-Scholes Option Pricing Model	The fair value of the BGU Options granted was $30 using the Black-Scholes option pricing model using the following assumptions: January Charging Robotics share price $ 7,410 Charging Robotics Exercise price $ 0 Dividend yield 0 % Risk-free interest rate 0.48 % Expected term (in years) 10 Volatility 75 %
Schedule of Stock Options Activity	A summary of stock options activity during the period is as follows: Number Average Options outstanding at December 31, 2021 18 $ 8,333 Granted 4 - Options outstanding at December 31, 2022 22 $ 6,818 Exercised (18 ) 8,333 Options outstanding at June 30, 2023 4 $ - Options exercisable at December 31, 2022 - $ -
Schedule of Stock Options Outstanding	The following Charging Robotics options are outstanding as of June 30, 2023: Issuance date Options Exercise Options Expiry date January 1, 2022 4 $ - - January 1, 2032 Issuance date Options Exercise Options Expiry date January 7, 2021 18 $ 8,333 18 January 7, 2026 January 1, 2022 4 $ - - January 1, 2032 22 18

General (Details)

General (Details) - USD ($) $ in Thousands		6 Months Ended
	Apr. 06, 2023	Jun. 30, 2023	Mar. 28, 2023
General (Details) [Line Items]
Issuance shares	136,500,000	921,750,000	921,750,000
Class of Warrant or Right, Outstanding		922,500,000
Total proceeds of private placement (in Dollars)	$ 500	$ 501
Charging Robotics [Member]
General (Details) [Line Items]
Acquired interest percentage		100%	100%

Unaudited Interim Condensed F_2

Unaudited Interim Condensed Financial Statements (Details)	6 Months Ended
	Jun. 30, 2023
Unaudited Interim Condensed Financial Statements (Details) [Line Items]
Tax benefit percentage	50%
Maximum [Member]
Unaudited Interim Condensed Financial Statements (Details) [Line Items]
Affiliated, percentage	20%
Minimum [Member]
Unaudited Interim Condensed Financial Statements (Details) [Line Items]
Affiliated, percentage	20%

Going Concern (Details)

Going Concern (Details) - USD ($) $ in Thousands	Jun. 30, 2023	Dec. 31, 2022
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Accumulated deficit	$ (1,504)	$ (1,188)

Investment in Affiliated Comp_3

Investment in Affiliated Company (Details) - USD ($)	1 Months Ended
	Apr. 24, 2021	Jun. 30, 2023	Jul. 28, 2022
Investment in Affiliated Company (Details) [Line Items]
Purchase percentage	19.99%
Principal amount			$ 340
Aggregate amount			1,000
Principal loan amount		$ 61
Robotics [Member]
Investment in Affiliated Company (Details) [Line Items]
Investments	$ 250
Revoltz [Member]
Investment in Affiliated Company (Details) [Line Items]
Investments			60
Aggregate amount			7,000
Aggregate revenue			$ 1,000

Investment in Affiliated Comp_4

Investment in Affiliated Company (Details) - Schedule of Equity Method Accounting For Investment in Affiliated Company - USD ($) $ in Thousands	6 Months Ended	12 Months Ended
	Jun. 30, 2023	Dec. 31, 2022
Schedule of Equity Method Accounting For Investment in Affiliated Company [Abstract]
Balance beginning	$ 152	$ 217
Share in losses of affiliated company	(11)	(42)
Foreign currency translation	(8)	(23)
Balance ending	$ 133	$ 152

Intangible Asset (Details) - Sc

Intangible Asset (Details) - Schedule of All Intangibles to be Definite-Lived Assets - USD ($) $ in Thousands	6 Months Ended	12 Months Ended
	Jun. 30, 2023	Dec. 31, 2022
Schedule of All Intangibles to be Definite Lived Assets [Abstract]
Beginning Balance	$ 74	$ 74
Ending Balance	85	74
Additions	$ 11

Related Parties (Details)

Related Parties (Details)	Jan. 01, 2023 USD ($)	Oct. 01, 2021 USD ($)	Oct. 01, 2021 ILS (₪)	Jun. 30, 2023 USD ($)	Jun. 30, 2022 USD ($)
Related Parties [Abstract]
Related party amount	$ 550
Annual percentage	2.42%
Related party description	Pursuant to the Medigus Loan Agreement, the interest rate remains unchanged, and the capital and interest will be repaid in cash or shares, or a combination thereof by the earlier of (i) the completion of the Medigus Transaction or (ii) June 30, 2023. On April 4, 2023, the Medigus Loan balance owing was $553. $509 of the Medigus Loan was converted into 28 shares of Charging Robotics and the balance will be repaid in cash.
Monthly fees		$ 7	₪ 24,700
Stock options percentage		3%	3%
Exercise price valuation		$ 10,000
CEO earned				$ 42	$ 42

Related Parties (Details) - Sch

Related Parties (Details) - Schedule of Compensation to Key Management Personnel for Employment Services - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2023	Jun. 30, 2022	Jun. 30, 2023	Jun. 30, 2022	Dec. 31, 2022
Segment Reporting Information [Line Items]
Total Consulting Fees	$ 66		$ 66		$ 595
CEO [Member]
Segment Reporting Information [Line Items]
Consulting Fees	21	$ 21	42	$ 42
Total Consulting Fees	14		14		28
CFO [Member]
Segment Reporting Information [Line Items]
Consulting Fees	11	$ 2	20	$ 6
Total Consulting Fees	4		4		17
Medigus [Member]
Segment Reporting Information [Line Items]
Total Consulting Fees	$ 48		$ 48		$ 550

Common Stock and Preferred St_3

Common Stock and Preferred Stock (Details) - USD ($) $ / shares in Units, $ in Thousands					1 Months Ended	6 Months Ended
	Apr. 06, 2023	Apr. 04, 2023	Apr. 03, 2023	Feb. 01, 2022	Mar. 28, 2023	Jun. 30, 2023	Jun. 30, 2022	Mar. 22, 2023	Dec. 31, 2022
Common Stock and Preferred Stock (Details) [Line Items]
Common Stock Shares Authorized						2,990,000,000		3,000,000,000	2,990,000,000
Shares par value (in Dollars per share)								$ 0.0001
Shares issued			7,636
Options exercised for total proceeds (in Dollars)			$ 91			$ 91
Shares issued			28
Percentage of shares issued and outstanding					72.88%
Common stock value total (in Dollars)	$ 501
Options granted (in Dollars)				$ 30
Share-based compensation expenses (in Dollars)						$ 7	$ 7
Common Stock [Member]
Common Stock and Preferred Stock (Details) [Line Items]
Common Stock Shares Authorized								2,990,000,000
Shares par value (in Dollars per share)								$ 0.0001
Preferred Stock [Member]
Common Stock and Preferred Stock (Details) [Line Items]
Common Stock Shares Authorized								10,000,000
Shares par value (in Dollars per share)								$ 0.0001
Warrant [Member]
Common Stock and Preferred Stock (Details) [Line Items]
Warrants exercisable						922,500,000
Investor [Member]
Common Stock and Preferred Stock (Details) [Line Items]
Issuance of shares	136,500,000
Charging Robotics [Member]
Common Stock and Preferred Stock (Details) [Line Items]
Acquired interest percentage					100%	100%
Issuance of shares		921,750,000
Acquisition Agreement [Member]
Common Stock and Preferred Stock (Details) [Line Items]
Shares issued			4,091

Common Stock and Preferred St_4

Common Stock and Preferred Stock (Details) - Schedule of Composed Share Capital - shares	Jun. 30, 2023	Mar. 22, 2023	Dec. 31, 2022
Schedule of Composed Share Capital [Abstract]
Shares of common stock (“Shares”), Authorized	2,990,000,000	3,000,000,000	2,990,000,000
Shares of common stock (“Shares”), Issued and outstanding	1,372,656,029		27,273
Preferred shares, Authorized	10,000,000		10,000,000
Preferred shares, Issued and outstanding

Common Stock and Preferred St_5

Common Stock and Preferred Stock (Details) - Schedule of Stock Options Granted Using Black-Scholes Option Pricing Model	12 Months Ended
	Jan. 31, 2022 $ / shares
Schedule of Stock Options Granted Using Black Scholes Option Pricing Model [Abstract]
Charging Robotics share price (in Dollars per share)	$ 7,410
Charging Robotics Exercise price (in Dollars per share)	$ 0
Dividend yield	0%
Risk-free interest rate	0.48%
Expected term (in years)	10 years
Volatility	75%

Common Stock and Preferred St_6

Common Stock and Preferred Stock (Details) - Schedule of Stock Options Activity - $ / shares	6 Months Ended	12 Months Ended
	Jun. 30, 2023	Dec. 31, 2022
Schedule of Stock Options Activity [Abstract]
Number Options outstanding Beginning balance	22	18
Average weighted exercise price Options outstanding Beginning balance	$ 6,818	$ 8,333
Number Options outstanding Ending balance	4	22
Average weighted exercise price Options outstanding Ending balance		$ 6,818
Number Options exercisable
Average weighted exercise price Options exercisable
Number Exercised	(18)
Average weighted exercise price Exercised	$ 8,333
Number Granted		4
Average weighted exercise price Granted

Common Stock and Preferred St_7

Common Stock and Preferred Stock (Details) - Schedule of Stock Options Outstanding - $ / shares	6 Months Ended	12 Months Ended
	Jun. 30, 2023	Dec. 31, 2022
Common Stock and Preferred Stock (Details) - Schedule of Stock Options Outstanding [Line Items]
Options outstanding		22
Options exercisable		18
January 1, 2022 [Member]
Common Stock and Preferred Stock (Details) - Schedule of Stock Options Outstanding [Line Items]
Options outstanding	4	4
Exercise price per option (in Dollars per share)
Options exercisable
Expiry date	January 1, 2032	January 1, 2032
January 7, 2021 [Member]
Common Stock and Preferred Stock (Details) - Schedule of Stock Options Outstanding [Line Items]
Options outstanding		18
Exercise price per option (in Dollars per share)		$ 8,333
Options exercisable		18
Expiry date		January 7, 2026

Subsequent Events (Details)

Subsequent Events (Details)	Jul. 04, 2023 shares
Subsequent Event [Member]
Subsequent Events (Details) [Line Items]
Issuance of shares	205,898,404